Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates
Viatris (VTRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.54 per share a year ago.
Viatris (VTRS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Viatris (VTRS) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
Upcoming launches between 2026–2027, including fast-acting meloxicam, cenerimod, and selatogrel, could support a return to mid-single-digit sales growth and improve margins. With FCF yield above 10% and solid deleveraging capacity, Viatris combines deep-value characteristics with optionality from targeted acquisitions and shareholder returns. VTRS also anticipates $500 million in net cost savings by 2028, with reinvestment supporting higher-value brands.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?
Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates
VTRS scores four regulatory wins in 2025, from FDA approval of a generic Sandostatin LAR to NDA and IND clearances across its pipeline.
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript
Viatris Inc. ( VTRS ) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Presentation Ashwani Verma UBS Investment Bank, Research Division Good day, everybody. My name is Ash Verma, I cover SMID-cap, biotech and spec pharma.
Viatris Inc. (VTRS) Q3 2025 Earnings Call Transcript
Viatris Inc. ( VTRS ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants William Szablewski Scott Smith - CEO & Director Philippe Martin - Chief R&D Officer Corinne Le Goff - Chief Commercial Officer Theodora Mistras - Chief Financial Officer Conference Call Participants Leszek Sulewski - Truist Securities, Inc., Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Ashwani Verma - UBS Investment Bank, Research Division David Amsellem - Piper Sandler & Co., Research Division Jason Gerberry - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Viatris Q3 2025 Earnings Call. [Operator Instructions] Please note, this event is being recorded.
